Skip to main content
Equibles
ARMP logo

ARMP · Armata Pharmaceuticals, Inc. · Metrics

Track ARMP — free

Use ARMP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARMP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.52 +0.21 (+6.34%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our existing cash and cash equivalents of $24.0 million as of June 30, 2026 will not be sufficient to enable us to complete all necessary development of any potential product candidates and fund our operations for the next 12 months from the date the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$133.67M
Shares
37.18M
Volume · Oct 2 124.48K Avg daily vol (3M) 213.34K

ARMP metrics

33 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.52
Market cap
$133.67M

Price action

20 metrics
Price change (1W)
-5.9%
Price change (30D)
-39.7%
Price change (3M)
-40.2%
Price change (6M)
-65.4%
Price change (YTD)
-43.9%
Price change (1Y)
+14.7%
Trailing year
Price change (5Y)
-2.8%
52-week high
$14.80
52-week low
$3.07
Change from 52-week high
-76.2%
Change from 52-week low
+14.7%
Annualized volatility
151.2%
Annualized volatility (3M)
113.8%
Beta
0.5
RSI (14D)
35.8
Price vs SMA 50
-25.0%
Price vs SMA 200
-51.8%
Avg volume (3M)
213,339
Relative volume
0.6
Average dollar volume
$1.05M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
37.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-25

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
53
13F filer change QoQ
+8
Institutional ownership
13.4%

Short interest

3 metrics
Short interest
2.6%
Latest settlement · 1.7 days to cover
Days to cover
1.7d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 921114 CUSIP 04216R102 13F (30d) 1 filings 1 filers Visit website Investor relations